Chronic Myocardial Infarction with Preserved Left Ventricular Ejection Fraction"
Conditions
Interventions
After confirming eligibility, cardiopulmonary exercise testing, transthoracic echocardiography, and blood tests will be conducted. Following these tests, the dose of beta blockers will be reduced to h
Sponsors
Juntendo University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The age at the time of consent acquisition is 20 years or older. 2. The individual has received a sufficient explanation regarding participation in this study, understood it fully, and provided written consent of their own free will. 3. At least six months have passed since the onset of myocardial infarction. 4. Left ventricular ejection fraction is preserved at 50 % or above. 5. The individual is currently taking beta blockers
Exclusion criteria
Exclusion criteria: 1. Individuals using implantable medical devices such as cardiac pacemakers or defibrillators. 2. Patients taking beta blockers for tachyarrhythmias. 3. Patients taking digitalis preparations, calcium channel blockers (verapamil, diltiazem), or ivabradine. 4. Patients diagnosed with acute phase of acute myocardial infarction, unstable angina not stable with medical treatment, uncontrolled arrhythmias causing symptoms or hemodynamic abnormalities, uncontrolled heart failure, uncontrolled hypertension, symptomatic severe aortic stenosis, or mental illness that precludes communication. Definition of heart failure symptoms: a) Dyspnea induced at rest or with mild exertion. b) At least two of the following: jugular venous distention, pulmonary rales, peripheral edema, or chest Xray showing pulmonary congestion. 5. Patients deemed unsuitable for the study by the principal investigator or co-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Parameters (PeakVO2) in Cardiopulmonary Exercise Testing After 4 Weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in Coronary Artery Disease Risk (blood pressure, lipid profile, diabetes biomarkers), Changes in Blood Test Parameters, Changes in Echocardiography Parameters, and the Occurrence of Events | — |
Countries
Japan
Contacts
Public ContactRyota Nishio
Juntendo University Graduate School of Medicine Department of Cardiovascular Biology and Medicine
Outcome results
None listed